Profile | GDS2987 / GI_19923163-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 30.4 | 64 |
GSM215244 | HMVEC_vehicle_rep2 | 13.1 | 33 |
GSM215253 | HMVEC_vehicle_rep3 | 22.1 | 56 |
GSM215254 | HMVEC_atorvastatin_rep1 | 23.8 | 52 |
GSM215282 | HMVEC_atorvastatin_rep3 | 18.6 | 40 |
GSM215344 | HMVEC_atorvastatin_rep2 | 42.2 | 65 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 2.7 | 5 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | ||
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | ||
GSM215294 | HMVEC_SLx2119_rep1 | 52.5 | 71 |
GSM215295 | HMVEC_SLx2119_rep2 | 40 | 60 |
GSM215296 | HMVEC_SLx2119_rep3 | 49.6 | 61 |
GSM215297 | PASMC_vehicle_rep1 | 19.6 | 30 |
GSM215298 | PASMC_vehicle_rep2 | 4.8 | 8 |
GSM215310 | PASMC_vehicle_rep3 | ||
GSM215311 | PASMC_atorvastatin_rep1 | 45.1 | 60 |
GSM215312 | PASMC_atorvastatin_rep2 | ||
GSM215313 | PASMC_atorvastatin_rep3 | 9.7 | 15 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 10 | 17 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 25 | 44 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | ||
GSM215327 | PASMC_SLx2119_rep1 | 34.5 | 51 |
GSM215328 | PASMC_SLx2119_rep2 | 23.7 | 40 |
GSM215329 | PASMC_SLx2119_rep3 | 66.1 | 70 |
GSM215330 | Fibroblasts_vehicle_rep1 | 22 | 45 |
GSM215331 | Fibroblasts_vehicle_rep2 | 21.7 | 50 |
GSM215332 | Fibroblasts_vehicle_rep3 | 19.8 | 52 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 29.6 | 58 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 57.7 | 70 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 28.7 | 55 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 41.6 | 67 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 30 | 63 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 18.7 | 46 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 62.9 | 71 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 38 | 65 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 34.9 | 61 |